Efficacy and dose confirmation in CTX-712 clinical trials for ovarian and hematologic cancers

A standalone clinical development topic covering CTX-712 (rogocekib), including the assessment of responders, response rates and complete responses in Phase 1 trials for ovarian and hematologic cancers, and the identification of an appropriate dosing regimen for transition to an expansion cohort.